deoxypyridinoline has been researched along with alendronate in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (27.27) | 18.2507 |
| 2000's | 22 (50.00) | 29.6817 |
| 2010's | 10 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M | 1 |
| Chesnut, CH; Eyre, DR; Genant, HK; Gertz, BJ; Hanson, DA; Harris, ST; Quan, H; Shao, P | 1 |
| Azuma, Y; Chokki, M; Kiyoki, M; Ohta, T | 1 |
| Altman, R; Conte, JM; Favus, M; Lombardi, A; Lyles, K; McIlwain, H; Murphy, WA; Reda, C; Rude, R; Seton, M; Siris, E; Thompson, D; Tiegs, R; Tucci, JR; Weinstein, RS; Yates, AJ; Zimering, M | 1 |
| Bettica, P; Bevilacqua, M; Cucinotta, E; Masino, M; Norbiato, G; Vago, T | 1 |
| Jilka, RL; Manolagas, SC; Munshi, M; Roberson, PK; Takahashi, K; Williams, DC | 1 |
| Fukunaga, M; Inoue, T; Kaneda, K; Kishimoto, H; Kushida, K; Minaguchi, H; Nagata, Y; Nakashima, M; Orimo, H; Shiraki, M; Tomita, A | 1 |
| Ferguson, L; Greenspan, SL; Karpf, DB; Maitland-Ramsey, L; Parker, RA; Rosen, HN | 1 |
| Bogado, C; Fradinger, EE; Rodriguez, G; Zanchetta, JR | 1 |
| Chang, SP; Chen, CR; Tsan, SH; Yang, TS; Yuan, CC | 1 |
| Becker, P; Watts, NB | 1 |
| Braga de Castro Machado, A; Eastell, R; Hannon, R | 1 |
| Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G | 1 |
| Adami, S; Braga, V; Gatti, D; Isaia, G; Rossini, M; Sartori, L | 1 |
| Iba, K | 1 |
| Arko, B; Kocijancic, A; Komel, R; Marc, J; Prezelj, J | 1 |
| Mossetti, G; Nappi, C; Numis, FG; Nunziata, V; Palomba, S; Rendina, D; Russo, T; Vuotto, P; Zullo, F | 1 |
| Baylink, DJ; Greenwald, M; Leenings, J; Libanati, C; Oberrauch, W; Srivastava, AK | 1 |
| Knecht, H; Kraenzlin, M; Lippuner, K; Michel, D; Perrelet, R; Risi, S; Zäch, GA; Zehnder, Y | 1 |
| Sarioglu, M; Taneli, F; Tikiz, C; Tuzun, C; Unlu, Z; Uyanik, BS | 1 |
| Alatas, O; Armagan, O; Colak, O; Oner, C; Tascioglu, F | 1 |
| Iba, K; Takada, J; Yamashita, T | 1 |
| Capar, M; Köşüş, A; Köşüş, N | 1 |
| Jhee, O; Kang, J; Kim, D; Kim, T; Lee, B; Lee, JW; Lee, M; Om, A; Park, SK; Yuan, H | 1 |
| Doolman, R; Eshed, V; Karasik, A; Sela, BA; Shimon, I; Vered, I | 1 |
| Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K | 1 |
| Benbassat, CA; Eshed, V; Laron, Z | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Takeda, T; Yamada, H; Yeh, JK | 1 |
| Asaba, Y; Harada, A; Hiramatsu, K; Ikeda, K; Ito, M; Katagiri, N; Kobayashi, T; Matsui, Y; Niida, S; Nimura, Y; Takewaka, T | 1 |
| Altundal, H; Göker, K; Sayrak, H; Yurtsever, E | 1 |
| Enishi, T; Kobayashi, T; Mitsuhashi, T; Miyamoto, M; Nishioka, T; Tamura, T; Yagi, S | 1 |
| Allen, MR; Burr, DB; Delmas, PD; Gineyts, E; Leeming, DJ | 1 |
| Fukunaga, M | 1 |
| Hayakawa, J; Isobe, A; Kimura, T; Mabuchi, S; Morishige, K; Nishio, Y; Ogata, S; Ohmichi, M; Sakata, M; Sawada, K | 1 |
| Chen, JF; Ho, C; Huang, YY; Hwang, JS; Lin, JD; Liou, MJ; Tsai, KS; Wang, CJ | 1 |
| Friedrich, NF; Graf, C; Kraenzlin, C; Kraenzlin, ME; Meier, C | 1 |
| Coelho, PG; Giro, G; Jorgetti, V; Marcantonio, E; Orrico, SR; Pereira, RM | 1 |
| Ho, HY; Ko, YJ; Lin, WC; Wu, JB | 1 |
| Endo, K; Mihara, M; Sakai, S; Shiraishi, A; Takeda, S | 1 |
| Cha, MR; Choi, YH; Davaatseren, M; Hur, HJ; Kim, HJ; Kwon, DY; Ryu, SY; Sung, MJ | 1 |
| Iwasaki, A; Matsui, Y; Minami, Y; Miyake, M; Ohbayashi, Y; Sawai, F | 1 |
| Choi, D; Choi, SJ; Kim, JH; Lee, DY; Min, YK; Yoon, BK | 1 |
| Liel, Y; Plakht, Y; Tailakh, MA | 1 |
| Cho, SH; Choi, YM; Lee, DY; Park, HM; Park, MC; Yoon, BK | 1 |
2 review(s) available for deoxypyridinoline and alendronate
| Article | Year |
|---|---|
[Treatment of male osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Calcium; Fractures, Stress; Humans; Male; Osteoporosis; Peptide Fragments; Procollagen; Reference Standards; Testosterone; Vitamin D | 2002 |
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Topics: Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Peptides | 2009 |
23 trial(s) available for deoxypyridinoline and alendronate
| Article | Year |
|---|---|
Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Topics: Alendronate; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxyproline; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Reproducibility of Results | 1994 |
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Biopsy; Bone and Bones; Calcium; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Pain; Phosphates; Radiography | 1996 |
Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
Topics: Adult; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Remodeling; Calcium Carbonate; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Peptides; Time Factors | 1997 |
A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Diseases, Metabolic; Calcium; Female; Humans; Japan; Kinetics; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphorus; Placebos | 1998 |
Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium, Dietary; Collagen; Collagen Type I; Double-Blind Method; Female; Femur; Humans; Osteocalcin; Peptides; Radius; Spine; Vitamin D | 1998 |
Effect of antiresorptive therapy on day-to-day variation of urinary free deoxypyridinoline excretion.
Topics: Aged; Alendronate; Amino Acids; Biomarkers; Bone Resorption; Enzyme-Linked Immunosorbent Assay; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1998 |
Effects of alendronate on bone turnover markers in early postmenopausal women.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone and Bones; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause | 1998 |
Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 1999 |
Monitoring alendronate therapy for osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Calcium Carbonate; Collagen; Collagen Type I; Female; Humans; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Peptides | 1999 |
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diphosphonates; Female; Humans; Infusions, Intravenous; Isoenzymes; Osteoporosis, Postmenopausal; Pamidronate; Structure-Activity Relationship; Triglycerides | 2000 |
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Calcium; Creatinine; Female; Femur; Humans; Hyperparathyroidism; Osteocalcin; Osteoporosis; Parathyroid Hormone; Phosphates; Pilot Projects; Random Allocation; Retrospective Studies | 2001 |
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.
Topics: Aged; Alendronate; Amino Acids; Biomarkers; Bone Density; Creatinine; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Prospective Studies; Receptors, Calcitriol; Treatment Outcome | 2003 |
Prevention of bone loss in paraplegics over 2 years with alendronate.
Topics: Adult; Alendronate; Amino Acids; Bone Density; Bone Remodeling; Bone Resorption; Calcium; Creatinine; Diaphyses; Epiphyses; Femur; Humans; Male; Paraplegia; Tibia | 2004 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Creatinine; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Topics: Absorptiometry, Photon; Administration, Inhalation; Administration, Intranasal; Alendronate; Alkaline Phosphatase; Amino Acids; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Calcium, Dietary; Female; Glucocorticoids; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal | 2005 |
Cyclical alendronate treatment in postmenopausal women with osteoporosis.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Phosphorus | 2005 |
Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Topics: Adult; Aged; Alendronate; Amino Acids; Androgens; Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Therapy, Combination; Femur Neck; Hormone Replacement Therapy; Humans; Hypogonadism; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Testosterone | 2005 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risk; Vitamin D Deficiency | 2006 |
Alendronate inhibits periprosthetic bone loss around uncemented femoral components.
Topics: Aged; Alendronate; Amino Acids; Bone Cements; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Female; Femur; Humans; Male; Middle Aged; Phosphorus; Prostheses and Implants | 2007 |
Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Lumbar Vertebrae; Middle Aged; Postmenopause; Radius; Tomography, X-Ray Computed | 2009 |
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Femur Neck; Humans; Isoenzymes; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Taiwan; Time Factors | 2010 |
Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Aged; Alendronate; Amino Acids; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Estrogen Replacement Therapy; Female; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Pelvic Bones; Placebos; Republic of Korea | 2013 |
Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
Topics: Aged; Alendronate; Amino Acids; Asian People; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Humans; Lumbar Vertebrae; Mastodynia; Medroxyprogesterone Acetate; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Republic of Korea | 2017 |
19 other study(ies) available for deoxypyridinoline and alendronate
| Article | Year |
|---|---|
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Clodronic Acid; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Hydroxyproline; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Osteoporosis; Peptides; Time Factors | 1995 |
Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin, synthetic eel calcitonin.
Topics: Alendronate; Amino Acids; Animals; Bone Resorption; Calcitonin; Calcium; Circadian Rhythm; Diphosphonates; Male; Phosphates; Rats; Rats, Sprague-Dawley | 1996 |
Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption.
Topics: Alendronate; Amino Acids; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Estrogens; Female; Humans; Mice; Osteoblasts; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Stem Cells | 1998 |
No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis.
Topics: Adult; Alendronate; Amino Acids; Base Sequence; Bone Density; Deoxyribonucleases, Type II Site-Specific; DNA Primers; Estrogen Receptor beta; Female; Genotype; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Polymerase Chain Reaction; Polymorphism, Genetic; Receptors, Estrogen; Restriction Mapping | 2002 |
Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Chromatography, High Pressure Liquid; Collagen Type I; Female; Humans; Linear Models; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Reagent Kits, Diagnostic; Reference Values | 2003 |
Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Female; Humans; Japan; Male; Osteitis Deformans; Osteogenesis; Peptides | 2005 |
Effect of Korean oriental medicine extract on bone mass as compared with alendronate in ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Remodeling; Bone Resorption; Calcium; Complementary Therapies; Female; Korea; Medicine, Traditional; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Spine | 2005 |
Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
Topics: Absorptiometry, Photon; Adult; Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conservation Agents; Female; Femur Neck; Humans; Insulin-Like Growth Factor I; Laron Syndrome; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prospective Studies | 2006 |
Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
Topics: Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcium; Female; Hydroxycholecalciferols; Osteocalcin; Ovariectomy; Phosphorus; Rats; Rats, Sprague-Dawley; Tibia | 2006 |
Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Female; gamma-Glutamyltransferase; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptides | 2006 |
Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
Topics: Alendronate; Amino Acids; Animals; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Calcitriol; Calcium; Creatinine; Male; Osteoclasts; Parathyroid Hormone; Rats; Rats, Wistar; Statistics, Nonparametric | 2007 |
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.
Topics: Alendronate; Amino Acids; Animals; Arginine; Bone Density Conservation Agents; Bone Remodeling; Collagen; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Lysine; Raloxifene Hydrochloride; Risedronic Acid | 2008 |
Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conservation Agents; Bone Marrow Diseases; Collagen Type I; Diphosphonates; Edema; Humans; Knee; Leg Bones; Magnetic Resonance Imaging; Middle Aged; Osteocalcin; Osteonecrosis; Pain Measurement; Pamidronate; Peptide Fragments; Peptides; Procollagen; Prospective Studies | 2010 |
The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dental Implants; Dental Materials; Disease Models, Animal; Estradiol; Estrogen Replacement Therapy; Female; Femur; Lumbar Vertebrae; Osseointegration; Osteocalcin; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Wistar; Tibia; Titanium | 2011 |
Antiosteoporotic activity of Davallia formosana.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Catechin; Cell Differentiation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Mice; Osteoclasts; Osteoporosis; Ovariectomy; Plant Extracts; Plants, Medicinal; Polypodiaceae; RANK Ligand; Rats; Rats, Wistar; Rhizome; Solvents; Time Factors; X-Ray Microtomography | 2012 |
Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Ovariectomy; Periosteum; Rats; Vitamin D; X-Ray Microtomography | 2012 |
Antiosteoporotic activity of Saururus chinensis extract in ovariectomized rats.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Body Weight; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Drug Evaluation, Preclinical; Female; Femur; Organ Size; Osteocalcin; Osteoporosis; Ovariectomy; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Saururaceae; Uterus; X-Ray Microtomography | 2012 |
Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Topics: Acid Phosphatase; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Collagen Type I; Female; Follow-Up Studies; Humans; Isoenzymes; Mandible; Mandibular Diseases; Osteocalcin; Osteogenesis; Peptide Fragments; Peptides; Procollagen; Radionuclide Imaging; Radiopharmaceuticals; Tartrate-Resistant Acid Phosphatase; Technetium Tc 99m Medronate; Teriparatide | 2013 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid | 2017 |